Compare Dyne Therapeutics Inc. Common Stock (DYN) vs PAGSEG Inc (PAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs PAGSEG Inc — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while PAGSEG Inc trades at $10.83 (market cap $3.03B). The key difference: Dyne Therapeutics Inc. Common Stock and PAGSEG Inc are close in size by market cap, and PAGSEG Inc pays a 10.19% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and PAGSEG Inc for 27 Days on average.
| DYN | PAGS | |
|---|---|---|
Market Cap | $2.86B | $3.03B |
Volume | 3,341,579 | 2,770,540 |
Sector | Health | Industrials |
52-Week High | $26.78 | $12.00 |
52-Week Low | $14.60 | $8.44 |
Typical Hold Time | 0 Days | 27 Days |
Enterprise Value | $2.18B | $11.16B |
Dividend Yield | — | 10.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
PAGS trades at $10.99, down 1.35% on the day, with a bullish technical signal from moving averages but overbought short-term RSI readings. The company reported a Q2 2026 EPS beat of $0.41 vs. $0.389 expected, with revenue growth to $20.6B in 2026 and a net income margin of 10.45%. A dividend of $0.28 is scheduled for payment on September 30, 2026.
The stock presents a value opportunity with low P/E (7.31) and P/S (0.76) ratios, supported by strong analyst consensus (62.5% buy ratings) and a $10.70 price target. Key risks include macroeconomic pressures in Brazil and elevated credit losses, but robust cash flow and banking growth underpin long-term potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →
